(0.24%) 5 144.00 points
(0.25%) 38 537 points
(0.35%) 17 909 points
(-0.78%) $83.20
(1.66%) $1.955
(-0.20%) $2 342.40
(1.04%) $27.54
(0.49%) $926.60
(-0.19%) $0.933
(-0.13%) $11.01
(-0.27%) $0.798
(0.75%) $92.57
@ $1.160
発行日: 14 2月 2024 @ 23:35
リターン: -5.17%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
本日の出来高 | 351 535 |
平均出来高 | 1.47M |
時価総額 | 192.92M |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.86 |
ATR14 | $0.00300 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Rojkjaer Lisa | Buy | 187 500 | Employee Stock Option (right to buy) |
2024-03-27 | Rojkjaer Lisa | Buy | 0 | |
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
93.23 |
Last 98 transactions |
Buy: 9 654 000 | Sell: 304 047 |
ボリューム 相関
Rigel Pharmaceuticals Inc 相関
10 最も正の相関 | |
---|---|
CRNC | 0.963 |
ROIV | 0.959 |
NLSP | 0.958 |
MLCO | 0.954 |
MOMO | 0.954 |
FXCO | 0.951 |
CTSO | 0.949 |
APAC | 0.948 |
VRDN | 0.946 |
BRAC | 0.945 |
10 最も負の相関 | |
---|---|
GRIN | -0.954 |
PIII | -0.939 |
RIVN | -0.938 |
SNPX | -0.925 |
OP | -0.924 |
SWAV | -0.923 |
ZENV | -0.923 |
LAWS | -0.919 |
NAKD | -0.916 |
ENPH | -0.916 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Rigel Pharmaceuticals Inc 相関 - 通貨/商品
Rigel Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $116.88M |
総利益: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2023 |
収益: | $116.88M |
総利益: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2022 |
収益: | $120.24M |
総利益: | $118.49M (98.55 %) |
EPS: | $-0.360 |
FY | 2021 |
収益: | $149.24M |
総利益: | $148.15M (99.27 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。